Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
Tempus Ai stock last closed at $40.98, up 1.31% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Internet Content & Information industry by N/A percentage points. Tempus Ai stock is currently +79.03% from its 52-week low of $22.89, and -55.19% from its 52-week high of $91.45.
At the moment, there are 172.21M TEM shares outstanding. The market cap of TEM is $7.06B. In the past 24 hours, 8.86M TEM shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy TEM stock.
Based on our analysis, eToro is the best brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen your brokerage, it's time to fill out some personal information so you are able to buy TEM stock today.
Now that you've created your account on stock apps to use, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring funds into your investment account.
Once you have figured out the best place to buy Tempus Ai stock, it's critical to evaluate their stock prior to investing, so you actually wrap your head around the risk as well as the opportunity.
WallStreetZen was created to help average investors perform more in-depth fundamental analysis.
You can view all of the due diligence checks on TEM's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge TEM's intrinsic value.
Using relative valuations ratios:
You can access more valuation analysis on TEM's stock here.
Out of 11 sell side analysts who track TEM, the consensus analyst rating on Tempus Ai is a Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Rachel Vatnsdal, a top 18% analyst from JP Morgan downgrades TEM to a hold rating and raises their TEM price target from $50.00 to $55.00, on Feb 25, 2025.
JP Morgan's Rachel Vatnsdal downgraded their rating on Tempus Ai (NASDAQ: TEM) from Strong Buy to Hold on 2025/02/25. The analyst also raised their price target by 10% from $50 to $55.
Tempus AI reported its Q4 and FY 2024 earnings.
The quarter's results were consistent with expectations, and management's FY 2025 guidance shows "sustainable" data and service revenue, "encouraging" average selling price traction, and increasing profitability, Vatnsdal told readers.
The analyst cited recent stories about AI and Nancy Pelosi's call option purchases for the increasing retail interest and the stock's 106% YTD share increase.
Following the stock price's recent surge, Vatnsdal said they "still" believe in Tempus AI's "unique combination" of data and diagnostics, although they consider the shares quite fully valued.
Tempus Ai reported:
For Q4 2024:
For FY 2024:
For FY 2025, management guided:
Founder & CEO Eric Lefkofsky commented: “Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year.
“We believe our investments in AI have positioned us well for the future, as technologies that seemed unimaginable a few short years ago increasingly allow us to make our diagnostics intelligent, helping patients live longer and healthier lives.
“We remain on track to achieve our key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025.”
Dan Brennan, a top 29% analyst from TD Cowen reinstates TEM with a strong buy rating and announces their TEM price target of $74.00, on Feb 5, 2025.
Mark Schappel, a bottom 13% analyst from Loop Capital maintains TEM with a strong buy rating and lowers their TEM price target from $57.00 to $52.00, on Jan 14, 2025.
Doug Schenkel, a bottom 12% analyst from Wolfe Research initiates coverage on TEM with a buy rating and announces their TEM price target of $60.00, on Dec 13, 2024.
Subbu Nambi, a bottom 12% analyst from Guggenheim initiates coverage on TEM with a strong buy rating and announces their TEM price target of $74.00, on Dec 9, 2024.
You can dive deeper into what analysts are forecasting on the Tempus Ai stock forecast page.
Last year, TEM revenue was $693.40M. Over the past two year, TEM's revenue has grown by 47.05% per year. This was faster than the Internet Content & Information industry average of 18.2%.
Dive into TEM's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at TEM have sold more shares than they have bought.
Jennifer A. Doudna, Director of TEM, was the latest TEM insider to sell. They sold $30,075.00 worth of TEM shares on Apr 1, 2025.
Get more info about who owns TEM shares here.
No, Tempus Ai doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
You have two main options:
Press the Open button and your broker will place the order.
If you need more help investing in stocks on eToro, watch the helpful video below:
Now that you own some shares in TEM, you'll want to stay up-to-date on your new stock purchase.
Start a watchlist to keep tabs on your TEM stock.
To reiterate, here are the 6 steps for buying Tempus Ai stock:
If you are looking for a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Tempus Ai, get started below.